Active Ingredient(s): Eravacycline Dihydrochloride
FDA Approved: * August 27, 2018
Category: Antibiotics

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Xerava Overview

Eravacycline (TP-434, Xerava) is a synthetic halogenated tetracycline class antibiotic in development by Tetraphase Pharmaceuticals. It is closely related to tigecycline. It has a broad spectrum of activity including many multi-drug resistant strains of bacteria. Phase III studies in complicated intra-abdominal infections (cIAI)[1] and complicated urinary tract infections (cUTI)[2] were recently completed with mixed results. Eravacycline has been granted fast t...

Read more Xerava Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Eravacycline

Recent Xerava Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Eravacycline Dihydrochloride
  • Powder: 100mg/vial, 50mg/vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Xerava: (1 result)

Sorted by National Drug Code
  • 71773-050 Xerava 50 mg Intravenous Injection, Powder, Lyophilized, for Solution by Tetraphase Pharmaceuticals, Inc.

Other drugs which contain Eravacycline Dihydrochloride or a similar ingredient: (1 result)